Transaction in Own Shares

PureTech Health PLC
08 November 2023
 

8 November 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:             

7 November 2023



Number of ordinary shares purchased:

24,745



Highest price paid per share:

163.00p



Lowest price paid per share:

159.00p



Volume weighted average price paid per share:

160.94p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,150,460 ordinary shares in treasury and has 273,317,699 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 273,317,699 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

07/11/2023

08:04:01

359

162.2

XLON

00377374135TRLO0.1.1

07/11/2023

09:27:26

359

162.6

BATE

00377394331TRLO0.1.1

07/11/2023

09:27:26

359

162.6

CHIX

00377394332TRLO0.1.1

07/11/2023

09:27:26

91

162.6

TRQX

00377394334TRLO0.1.1

07/11/2023

09:27:26

359

163

XLON

00377394333TRLO0.1.1

07/11/2023

09:27:26

128

162.6

BATE

00377394336TRLO0.1.1

07/11/2023

09:27:26

231

162.6

BATE

00377394335TRLO0.1.1

07/11/2023

09:27:26

91

162.6

TRQX

00377394338TRLO0.1.1

07/11/2023

09:27:26

359

162.6

BATE

00377394337TRLO0.1.1

07/11/2023

09:27:26

359

162.6

CHIX

00377394340TRLO0.1.1

07/11/2023

09:27:26

91

162.6

TRQX

00377394339TRLO0.1.1

07/11/2023

09:27:26

288

162.6

CHIX

00377394342TRLO0.1.1

07/11/2023

09:27:26

71

162.6

CHIX

00377394341TRLO0.1.1

07/11/2023

09:28:21

225

161.8

AQXE

00377394578TRLO0.1.1

07/11/2023

09:28:21

105

161.8

AQXE

00377394579TRLO0.1.1

07/11/2023

09:28:46

172

162

XLON

00377394620TRLO0.1.1

07/11/2023

09:28:46

187

162

XLON

00377394621TRLO0.1.1

07/11/2023

09:55:28

120

161.8

AQXE

00377400282TRLO0.1.1

07/11/2023

09:55:28

225

161.8

AQXE

00377400283TRLO0.1.1

07/11/2023

09:55:28

359

161.8

XLON

00377400284TRLO0.1.1

07/11/2023

09:55:28

359

161.8

XLON

00377400285TRLO0.1.1

07/11/2023

09:55:28

44

161.8

XLON

00377400286TRLO0.1.1

07/11/2023

09:55:28

288

161.8

XLON

00377400287TRLO0.1.1

07/11/2023

09:55:28

27

161.8

XLON

00377400288TRLO0.1.1

07/11/2023

10:20:18

359

161

XLON

00377405973TRLO0.1.1

07/11/2023

10:20:18

10

161

XLON

00377405975TRLO0.1.1

07/11/2023

10:20:18

93

161

XLON

00377405974TRLO0.1.1

07/11/2023

10:20:18

359

161

XLON

00377405976TRLO0.1.1

07/11/2023

10:20:18

256

161

XLON

00377405977TRLO0.1.1

07/11/2023

11:07:42

600

160.2

XLON

00377417243TRLO0.1.1

07/11/2023

11:07:42

477

160.2

XLON

00377417244TRLO0.1.1

07/11/2023

11:26:13

461

159

XLON

00377420767TRLO0.1.1

07/11/2023

11:26:13

616

159

XLON

00377420768TRLO0.1.1

07/11/2023

11:26:24

359

159

XLON

00377420780TRLO0.1.1

07/11/2023

12:59:31

549

159

XLON

00377440548TRLO0.1.1

07/11/2023

12:59:32

50

159

XLON

00377440549TRLO0.1.1

07/11/2023

12:59:32

335

159

XLON

00377440550TRLO0.1.1

07/11/2023

12:59:32

16

159

XLON

00377440551TRLO0.1.1

07/11/2023

14:10:16

316

161.2

XLON

00377459061TRLO0.1.1

07/11/2023

14:16:16

343

161.2

XLON

00377461015TRLO0.1.1

07/11/2023

14:21:16

359

161

BATE

00377462860TRLO0.1.1

07/11/2023

14:21:16

359

161

BATE

00377462861TRLO0.1.1

07/11/2023

14:21:16

777

161.2

XLON

00377462862TRLO0.1.1

07/11/2023

14:21:16

675

161.2

XLON

00377462863TRLO0.1.1

07/11/2023

14:21:16

359

160.4

CHIX

00377462864TRLO0.1.1

07/11/2023

14:35:16

235

160.2

XLON

00377469888TRLO0.1.1

07/11/2023

14:38:23

91

160.2

TRQX

00377471652TRLO0.1.1

07/11/2023

14:38:23

91

160.2

TRQX

00377471653TRLO0.1.1

07/11/2023

14:40:08

1050

161

BATE

00377472616TRLO0.1.1

07/11/2023

14:42:44

386

161

BATE

00377473581TRLO0.1.1

07/11/2023

15:09:55

359

160.8

BATE

00377486058TRLO0.1.1

07/11/2023

15:32:42

2249

161

CHIX

00377496641TRLO0.1.1

07/11/2023

15:33:45

982

161

CHIX

00377497180TRLO0.1.1

07/11/2023

15:33:52

1795

160.8

XLON

00377497272TRLO0.1.1

07/11/2023

15:34:42

313

160.6

XLON

00377497861TRLO0.1.1

07/11/2023

15:35:24

91

160.2

TRQX

00377498040TRLO0.1.1

07/11/2023

15:35:24

148

160.4

BATE

00377498039TRLO0.1.1

07/11/2023

15:35:24

1123

160.6

XLON

00377498041TRLO0.1.1

07/11/2023

15:35:42

223

160.4

AQXE

00377498103TRLO0.1.1

07/11/2023

15:35:42

359

160.4

CHIX

00377498104TRLO0.1.1

07/11/2023

15:35:47

124

160.2

AQXE

00377498113TRLO0.1.1

07/11/2023

15:35:47

2

160.4

AQXE

00377498114TRLO0.1.1

07/11/2023

15:35:47

211

160.4

BATE

00377498115TRLO0.1.1

07/11/2023

15:35:47

101

160.2

AQXE

00377498116TRLO0.1.1

07/11/2023

15:35:52

29

160.2

AQXE

00377498148TRLO0.1.1

07/11/2023

15:56:56

172

161.2

XLON

00377509395TRLO0.1.1

07/11/2023

16:24:06

359

160.4

CHIX

00377526020TRLO0.1.1

07/11/2023

16:24:06

443

160.4

XLON

00377526021TRLO0.1.1

07/11/2023

16:29:49

246

160.6

XLON

00377531036TRLO0.1.1

07/11/2023

16:29:50

2

160.6

XLON

00377531040TRLO0.1.1

07/11/2023

16:29:55

556

160.6

XLON

00377531140TRLO0.1.1

07/11/2023

16:29:57

21

160.6

XLON

00377531150TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings